May 28, 2013 | Valeant Pharmaceuticals International of Canada has purchased Bausch & Lomb, the eye care company, for about $8.7 billion. Valeant will pay $4.5 billion to the investor group that owns Bausch & Lomb, and about $4.2 billion to repay Bausch & Lomb’s debt. New York Times Dealbook